Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation

J. Yuan, J. C. Hernandez, S. K. Ratuapli, K. C. Ruff, G. De Petris, D. M. Lam-Himlin, G. E. Burdick, Rahul Pannala, Francisco C Ramirez, D. E. Fleischer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and study aim: Radiofrequency ablation (RFA) to treat Barretts esophagus is increasingly accepted. Description of the etiology, natural history, and prevalence of buried Barretts metaplasia (BBM) following RFA is limited, although BBM continues to pose a clinical dilemma. We aimed to assess the prevalence, characteristics, and eradication rate of BBM in patients with both dysplastic and nondysplastic Barretts esophagus, treated with RFA and followed over time. Patients and methods: The presence of Barretts esophagus, dysplasia, and BBM, before and after RFA, was assessed by two gastrointestinal pathologists in a retrospective chart review of patients who had undergone RFA at our center and had completed appropriate follow-up. Results: We identified 112 patients with completed treatment and no further planned RFA. In 108, no residual Barretts esophagus was seen after RFA; 4 patients with persistent Barretts tissue underwent surgery. Regarding BBM, 17/112 patients (15.2%) had evidence of BBM during evaluation. In 12/17 (70.5%) BBM was found during the RFA treatment, with 8 having previously undergone non-RFA therapy and RFA for Barretts esophagus and 4 having no previous intervention. In 5/17 (29.4%), BBM was seen only after RFA monotherapy. All 17 showed no evidence of BBM at final evaluation and were classified in the complete remission group (108/112). Conclusion: Both Barretts esophagus and BBM were completely eradicated in all patients with long-term follow-up after RFA. Almost half of the patients with BBM had a prior history of non-RFA therapy for Barretts esophagus compared with 26% the non-BBM cohort. All patients with previously identified Barretts esophagus and BBM were completely cleared of disease at final follow-up.

Original languageEnglish (US)
Pages (from-to)993-997
Number of pages5
JournalEndoscopy
Volume44
Issue number11
DOIs
StatePublished - 2012

Fingerprint

Barrett Esophagus

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Yuan, J., Hernandez, J. C., Ratuapli, S. K., Ruff, K. C., De Petris, G., Lam-Himlin, D. M., ... Fleischer, D. E. (2012). Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation. Endoscopy, 44(11), 993-997. https://doi.org/10.1055/s-0032-1325678

Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation. / Yuan, J.; Hernandez, J. C.; Ratuapli, S. K.; Ruff, K. C.; De Petris, G.; Lam-Himlin, D. M.; Burdick, G. E.; Pannala, Rahul; Ramirez, Francisco C; Fleischer, D. E.

In: Endoscopy, Vol. 44, No. 11, 2012, p. 993-997.

Research output: Contribution to journalArticle

Yuan, J, Hernandez, JC, Ratuapli, SK, Ruff, KC, De Petris, G, Lam-Himlin, DM, Burdick, GE, Pannala, R, Ramirez, FC & Fleischer, DE 2012, 'Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation', Endoscopy, vol. 44, no. 11, pp. 993-997. https://doi.org/10.1055/s-0032-1325678
Yuan J, Hernandez JC, Ratuapli SK, Ruff KC, De Petris G, Lam-Himlin DM et al. Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation. Endoscopy. 2012;44(11):993-997. https://doi.org/10.1055/s-0032-1325678
Yuan, J. ; Hernandez, J. C. ; Ratuapli, S. K. ; Ruff, K. C. ; De Petris, G. ; Lam-Himlin, D. M. ; Burdick, G. E. ; Pannala, Rahul ; Ramirez, Francisco C ; Fleischer, D. E. / Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation. In: Endoscopy. 2012 ; Vol. 44, No. 11. pp. 993-997.
@article{4d55f3f222f84281aae4b591ea7e0d3e,
title = "Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation",
abstract = "Background and study aim: Radiofrequency ablation (RFA) to treat Barretts esophagus is increasingly accepted. Description of the etiology, natural history, and prevalence of buried Barretts metaplasia (BBM) following RFA is limited, although BBM continues to pose a clinical dilemma. We aimed to assess the prevalence, characteristics, and eradication rate of BBM in patients with both dysplastic and nondysplastic Barretts esophagus, treated with RFA and followed over time. Patients and methods: The presence of Barretts esophagus, dysplasia, and BBM, before and after RFA, was assessed by two gastrointestinal pathologists in a retrospective chart review of patients who had undergone RFA at our center and had completed appropriate follow-up. Results: We identified 112 patients with completed treatment and no further planned RFA. In 108, no residual Barretts esophagus was seen after RFA; 4 patients with persistent Barretts tissue underwent surgery. Regarding BBM, 17/112 patients (15.2{\%}) had evidence of BBM during evaluation. In 12/17 (70.5{\%}) BBM was found during the RFA treatment, with 8 having previously undergone non-RFA therapy and RFA for Barretts esophagus and 4 having no previous intervention. In 5/17 (29.4{\%}), BBM was seen only after RFA monotherapy. All 17 showed no evidence of BBM at final evaluation and were classified in the complete remission group (108/112). Conclusion: Both Barretts esophagus and BBM were completely eradicated in all patients with long-term follow-up after RFA. Almost half of the patients with BBM had a prior history of non-RFA therapy for Barretts esophagus compared with 26{\%} the non-BBM cohort. All patients with previously identified Barretts esophagus and BBM were completely cleared of disease at final follow-up.",
author = "J. Yuan and Hernandez, {J. C.} and Ratuapli, {S. K.} and Ruff, {K. C.} and {De Petris}, G. and Lam-Himlin, {D. M.} and Burdick, {G. E.} and Rahul Pannala and Ramirez, {Francisco C} and Fleischer, {D. E.}",
year = "2012",
doi = "10.1055/s-0032-1325678",
language = "English (US)",
volume = "44",
pages = "993--997",
journal = "Endoscopy",
issn = "0013-726X",
publisher = "Georg Thieme Verlag",
number = "11",

}

TY - JOUR

T1 - Prevalence of buried Barretts metaplasia in patients before and after radiofrequency ablation

AU - Yuan, J.

AU - Hernandez, J. C.

AU - Ratuapli, S. K.

AU - Ruff, K. C.

AU - De Petris, G.

AU - Lam-Himlin, D. M.

AU - Burdick, G. E.

AU - Pannala, Rahul

AU - Ramirez, Francisco C

AU - Fleischer, D. E.

PY - 2012

Y1 - 2012

N2 - Background and study aim: Radiofrequency ablation (RFA) to treat Barretts esophagus is increasingly accepted. Description of the etiology, natural history, and prevalence of buried Barretts metaplasia (BBM) following RFA is limited, although BBM continues to pose a clinical dilemma. We aimed to assess the prevalence, characteristics, and eradication rate of BBM in patients with both dysplastic and nondysplastic Barretts esophagus, treated with RFA and followed over time. Patients and methods: The presence of Barretts esophagus, dysplasia, and BBM, before and after RFA, was assessed by two gastrointestinal pathologists in a retrospective chart review of patients who had undergone RFA at our center and had completed appropriate follow-up. Results: We identified 112 patients with completed treatment and no further planned RFA. In 108, no residual Barretts esophagus was seen after RFA; 4 patients with persistent Barretts tissue underwent surgery. Regarding BBM, 17/112 patients (15.2%) had evidence of BBM during evaluation. In 12/17 (70.5%) BBM was found during the RFA treatment, with 8 having previously undergone non-RFA therapy and RFA for Barretts esophagus and 4 having no previous intervention. In 5/17 (29.4%), BBM was seen only after RFA monotherapy. All 17 showed no evidence of BBM at final evaluation and were classified in the complete remission group (108/112). Conclusion: Both Barretts esophagus and BBM were completely eradicated in all patients with long-term follow-up after RFA. Almost half of the patients with BBM had a prior history of non-RFA therapy for Barretts esophagus compared with 26% the non-BBM cohort. All patients with previously identified Barretts esophagus and BBM were completely cleared of disease at final follow-up.

AB - Background and study aim: Radiofrequency ablation (RFA) to treat Barretts esophagus is increasingly accepted. Description of the etiology, natural history, and prevalence of buried Barretts metaplasia (BBM) following RFA is limited, although BBM continues to pose a clinical dilemma. We aimed to assess the prevalence, characteristics, and eradication rate of BBM in patients with both dysplastic and nondysplastic Barretts esophagus, treated with RFA and followed over time. Patients and methods: The presence of Barretts esophagus, dysplasia, and BBM, before and after RFA, was assessed by two gastrointestinal pathologists in a retrospective chart review of patients who had undergone RFA at our center and had completed appropriate follow-up. Results: We identified 112 patients with completed treatment and no further planned RFA. In 108, no residual Barretts esophagus was seen after RFA; 4 patients with persistent Barretts tissue underwent surgery. Regarding BBM, 17/112 patients (15.2%) had evidence of BBM during evaluation. In 12/17 (70.5%) BBM was found during the RFA treatment, with 8 having previously undergone non-RFA therapy and RFA for Barretts esophagus and 4 having no previous intervention. In 5/17 (29.4%), BBM was seen only after RFA monotherapy. All 17 showed no evidence of BBM at final evaluation and were classified in the complete remission group (108/112). Conclusion: Both Barretts esophagus and BBM were completely eradicated in all patients with long-term follow-up after RFA. Almost half of the patients with BBM had a prior history of non-RFA therapy for Barretts esophagus compared with 26% the non-BBM cohort. All patients with previously identified Barretts esophagus and BBM were completely cleared of disease at final follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84867791575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867791575&partnerID=8YFLogxK

U2 - 10.1055/s-0032-1325678

DO - 10.1055/s-0032-1325678

M3 - Article

C2 - 23108770

AN - SCOPUS:84867791575

VL - 44

SP - 993

EP - 997

JO - Endoscopy

JF - Endoscopy

SN - 0013-726X

IS - 11

ER -